We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Phosphagen. | LSE:PSG | London | Ordinary Share | AU000000POH7 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.25 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
20/3/2006 17:14 | what????????????!!!! | rambutan2 | |
20/3/2006 16:06 | Flint, I too was overcome by its lack of succinctness. | spaceparallax | |
20/3/2006 14:14 | Cripes - that is a long read...didnt make too much of it unfortunately | flintsurfer | |
14/3/2006 10:55 | We're due some news here surely. About to go away for 3 weeks. I bet it all happens when I'm not here....... : ) | worc0670 | |
10/3/2006 02:02 | hi suesean, i dont hold een, but do share an interest in syria via its partner, gpx. yes, whole bio climate is looking good for psg's prospects and im happy to sit. another one of mine, ymba, which is also a bio, has suddenly sprung into life after a few years of little on the share price front. as you say, psg's day will come. | rambutan2 | |
10/3/2006 01:43 | rambutan2 Thanks for the post on een. Still hold psg, bottom draw,our day will come. | suesean1 | |
01/3/2006 23:38 | i find the trading in this one odd. so many sells. is someone arbing from oz? if does get a mention then can spike up nicely, but will no doubt once more be pulled back down by those sells, if they continue. wonder what the cs view is? they look a bit silly putting out such a bullish note and seeing the price fall to under half their target. ho hum. | rambutan2 | |
01/3/2006 20:45 | tick up today due to mention in shares mag? only speculating. | lgw | |
25/2/2006 00:16 | finals were issued on 28/02 last year - could certainly do with a bit of a booster/publicity. that said, the current level offers nice chance to buy in/top up at not much above recent 10p placing price. one day this will come out of sleeper mode... | rambutan2 | |
15/2/2006 11:35 | currently just under 10p to buy in oz - don't really see why should have to pay such a premium to buy on aim! | rambutan2 | |
31/1/2006 00:07 | Me too - risk reward ratio is fantastic for psg. Would be nice for it to pay off sometime soon with some decent rises. Absolutely willing to be patient but I've been holding for some time now, well, about one year..... If the buy price goes anywhere near 11p I'll be adding some more. What other stocks are you guys in? I'm in SCR, SOV and ZBA (currently suspended). I've been looking at AGY but not sure about the competition they're facing..... cheers | worc0670 | |
30/1/2006 23:56 | yes. nothing i didnt know about but greater detail than other reports. what ive always liked about psg is the spread of possibilities that their portfolio offers. shorter term, the best bet is prob good news coming from alza (jnj). longer term, well there's just too many to choose from! | rambutan2 | |
30/1/2006 23:34 | rambutan2 did you manage to read the 28 pages ? looks good 3-6 months so tuck them away imo | lgw | |
30/1/2006 14:14 | many thanks for that lgw, you're a star. | rambutan2 | |
27/1/2006 21:07 | copied fromlonger report above for those who cant be bothered to read News Flow Outlook 2006 Functional foods licensing deal Clinical data from human trials of Ester E Initiation of Phase II clinical trials for TPM-01/Morphine Initiation of human trials for TPM-01/Insulin Partner signed for development of TPM-01/Morphine / Pain Portfolio Preclinical data from plaque reduction studies with APA-01 Launch of Phospha E as a dietary supplement in Australia Initiation of full clinical development programme from ALZA collaboration Clinical data from Phase II trials for TPM-01/Morphine QLT acquired Atrix Laboratories for $855m in stock and cash Cephalon acquired CIMA Labs for $515m in cash ALZA (JnJ) could be a potential acquirer of PSG's drug delivery and drug enhancement platforms | lgw | |
27/1/2006 20:52 | remaining pages from my previous post | lgw | |
27/1/2006 20:32 | Warning extremely long post 28 pages which I will delete from this post this sunday night. . | lgw | |
27/1/2006 10:22 | and the other half? lgw, could you give us a few tasty sentences, or rev projections or anything to chew on over the weekend? | rambutan2 | |
27/1/2006 09:32 | read half of the Collins Stewart note, excellent stuff. | lgw | |
24/1/2006 02:34 | Animal experiments to start on their anti platelet drug (released to Aussie Market 24TH Jan) cmp - hope all is well - I`ll be watching you Focker | flintsurfer | |
23/1/2006 14:56 | so with all this - why are shares being marked down every day.... | jaydeee | |
22/1/2006 16:33 | BBY has come up with the same valuation then 30p per share, albeit this was in November before recent news. | lgw | |
21/1/2006 12:56 | Haven't seen Collins stewart but the Aussie broker's report is on the website... | worc0670 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions